Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.59 Insider Own2.28% Shs Outstand44.10M Perf Week20.18%
Market Cap197.35M Forward P/E- EPS next Y-1.05 Insider Trans7.36% Shs Float20.37M Perf Month14.23%
Income-25.80M PEG- EPS next Q-0.19 Inst Own- Short Float5.54% Perf Quarter73.13%
Sales0.00M P/S- EPS this Y-31.33% Inst Trans-11.39% Short Ratio7.18 Perf Half Y211.51%
Book/sh3.19 P/B2.97 EPS next Y-32.74% ROA-16.68% Short Interest1.13M Perf Year186.97%
Cash/sh6.82 P/C1.39 EPS next 5Y- ROE-17.05% 52W Range2.56 - 11.67 Perf YTD43.48%
Dividend Est.- P/FCF- EPS past 5Y25.04% ROI-18.31% 52W High-18.85% Beta1.64
Dividend TTM- Quick Ratio40.75 Sales past 5Y0.00% Gross Margin- 52W Low269.92% ATR (14)0.85
Dividend Ex-Date- Current Ratio40.75 EPS Y/Y TTM21.28% Oper. Margin0.00% RSI (14)56.67 Volatility9.42% 10.12%
Employees50 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price19.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q11.63% Payout- Rel Volume0.97 Prev Close9.50
Sales Surprise- EPS Surprise16.67% Sales Q/Q- EarningsFeb 13 BMO Avg Volume157.19K Price9.47
SMA201.34% SMA5014.87% SMA200100.64% Trades Volume151,929 Change-0.32%
Date Action Analyst Rating Change Price Target Change
Jun-26-23Resumed Oppenheimer Outperform $17
Mar-04-21Initiated Piper Sandler Overweight $50
Jan-11-21Reiterated H.C. Wainwright Buy $10 → $17
Nov-02-20Initiated Jefferies Buy $17
Oct-25-19Initiated Oppenheimer Outperform $8
Feb-26-24 01:14PM
Feb-14-24 04:35AM
Feb-13-24 07:25AM
Feb-07-24 08:47PM
08:00AM Loading…
Feb-06-24 08:00AM
Jan-25-24 10:00AM
Dec-21-23 04:13PM
Dec-12-23 12:03PM
Nov-23-23 11:05AM
Nov-21-23 08:00AM
Nov-08-23 08:00AM
05:51PM Loading…
Nov-06-23 05:51PM
Oct-30-23 10:59AM
Oct-26-23 05:41PM
Oct-21-23 09:00AM
Sep-18-23 07:00AM
Aug-31-23 07:00AM
Aug-14-23 08:43AM
Aug-08-23 07:17AM
Jun-06-23 07:00AM
Jun-01-23 07:00AM
May-24-23 11:04AM
May-18-23 06:25AM
May-11-23 07:00AM
May-09-23 07:19AM
07:00AM Loading…
Apr-18-23 07:00AM
Apr-12-23 07:00AM
Mar-08-23 07:00AM
Mar-07-23 05:19AM
Feb-23-23 05:43AM
Feb-13-23 05:00PM
Feb-07-23 07:00AM
Feb-02-23 04:01PM
Jan-25-23 05:39AM
Jan-06-23 07:04AM
Dec-21-22 05:07PM
Dec-19-22 08:11AM
Dec-15-22 08:30AM
Dec-13-22 07:00AM
Nov-14-22 09:25AM
Nov-10-22 07:00AM
Oct-31-22 11:13AM
Oct-26-22 04:01PM
Sep-13-22 07:00AM
Aug-10-22 06:40AM
Aug-04-22 07:00AM
Jul-11-22 07:23AM
Jun-30-22 06:21PM
Jun-28-22 06:29AM
Jun-27-22 04:01PM
Jun-02-22 07:00AM
May-27-22 08:12AM
May-10-22 07:00AM
Apr-26-22 04:30PM
Apr-25-22 10:20AM
Apr-08-22 01:00PM
Mar-10-22 04:05PM
Mar-09-22 11:34PM
Mar-08-22 04:30PM
Feb-04-22 05:16AM
Feb-03-22 07:00AM
Jan-19-22 07:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-11-21 05:38AM
Dec-08-21 09:38AM
Nov-22-21 09:20AM
Nov-18-21 07:00AM
Nov-08-21 07:00AM
Oct-28-21 04:05PM
Oct-19-21 01:21PM
Oct-07-21 10:25AM
Aug-31-21 04:05PM
Aug-24-21 06:30AM
Aug-16-21 02:32PM
Jul-13-21 12:38PM
May-25-21 07:00AM
May-10-21 10:59AM
May-06-21 07:01AM
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Virsik PeterChief Operating OfficerFeb 06Option Exercise3.2372,782235,08686,110Feb 07 11:29 AM
Virsik PeterChief Operating OfficerFeb 06Sale10.2972,782748,92713,328Feb 07 11:29 AM
Virsik PeterChief Operating OfficerFeb 05Option Exercise3.235001,61513,828Feb 06 08:27 AM
Virsik PeterChief Operating OfficerFeb 05Sale9.581,19411,44013,328Feb 06 08:27 AM
Virsik PeterChief Operating OfficerJan 16Option Exercise3.231,7185,54915,740Jan 17 08:57 PM
Virsik PeterChief Operating OfficerJan 16Sale10.011,71817,19714,022Jan 17 08:57 PM
Virsik PeterChief Operating OfficerJan 05Sale6.116994,27114,022Jan 08 08:06 PM
Parkinson David RossChief Executive OfficerDec 14Buy2.309,22321,21365,675Dec 18 09:57 PM
BERGER FRANKLIN MDirectorNov 21Buy5.7323,259133,274784,404Nov 22 06:22 PM
BERGER FRANKLIN MDirectorNov 03Buy5.9916,47198,661760,875Nov 16 05:45 PM
BERGER FRANKLIN MDirectorNov 02Buy5.3560,000321,000744,404Nov 16 05:45 PM